The Competition and Markets (Authority) has concluded following new evidence, that extra remedies in London's private healthcare market such as price controls would not be proportionate as part of its investigation into the UK private healthcare market.
Two of the CMA members dissented from this decision. Insurer Bupa described the final decision from the watchdog as "extraordinary" and it "had failed to find a solution." The Competition Commission, a predecessor body of the Competition and Markets Authority (CMA), started a market investigation into private healthcare in April 2012, which reported in April 2014, immediately after the establishment of the CMA. The report concluded that certain features of the markets for privately-funded healthcare services were leading to adverse effects on competition (AEC). A number of remed...
To continue reading this article...
Join COVER for free
Signup and gain exclusive members-only insights
- Unlimited access to real-time news, key trend analysis and industry insights.
- Stay on top of the latest developments around health and wellbeing, diversity and inclusion and the cost of living crisis.
- Receive breaking news stories straight to your inbox in the daily newsletter.
- Members only access to monthly programme 'The COVER Review'
- Be the first to hear about our CPD accredited events and awards programmes.
